Breast surgery for low-grade ductal carcinoma may not improve survival
the ONA take:
According to a new study published in JAMA Surgery, researchers from Brigham and Women's Hospital in Boston, Massachusetts, have found that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) experienced no difference in survival compared with those who did not receive surgery.
For the retrospective analysis, researchers analyzed data from over 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database between 1998 and 2011. All patients were treated at Dana-Farber/Brigham and Women's Cancer Center.
Results showed that patients with low-grade DCIS who did not receive surgery at or shortly after diagnosis had a 10-year survival rate of 98.8% compared with 98.6% for those who did receive surgery; however, women with intermediate- or high-grade DCIS, the survival rate was significantly higher for those who had surgery versus those who did not.
The researchers note that a prospective clinical trial is warranted before it can be concluded that breast surgery should be avoided for women with low-grade DCIS.
Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ experienced no difference in survival.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|